Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4)
Latest & greatest articles for colorectal cancer
The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on colorectal cancer or other clinical topics then use Trip today.
This page lists the very latest high quality evidence on colorectal cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.
What is Trip?
Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.
Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.
As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.
For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via email@example.com
, SMAD4, BMPR1A, MLH1, MSH2, MSH6, PMS2, STK11, GREM1, MUTYH, and EPCAM* [*deletions associated with epigenetic silencing of MSH2]. Generally for the gastrointestinal (GI) cancer predisposition genes, those testing positive require close surveillance with colonoscopy to detect the rapidly growing cancers which occur driven by, for example, the mutator phenotype (accumulating hundreds of mutations in the tumours) typically of Lynch Syndrome. Those who do develop colorectalcancer are usually advised (...) ). MSAC acknowledged that the application may have benefited from PASC consideration. The comparator clinical pathway was largely accepted as ‘no testing’, although MSAC noted that the comparator for LS in the model was ‘immunohistochemistry + no genetic testing’. MSAC considered this to be appropriate, as current guidelines (Cancer Council Australia 2017 and NICE 2017) indicate that all colorectalcancers should undergo immunohistochemistry to detect mismatch repair proteins as a first step. MSAC
P623 Colorectalcancer, colectomy rates and inflammatory bowel disease activity following liver transplantation in primary sclerosing cholangitis: a systematic review and meta-analysis Validate User We are sorry, but we are experiencing unusual traffic at this time. Please help us confirm that you are not a robot and we will take you to your content. Could not validate captcha. Please try again. Take me to my Content
Adjuvant Chemotherapy of Locally Advanced ColonCancer: Final Results of a Randomized Trial Comparing 5-Fluorouracil and Folinic Acid with Folfiri. There is still the need to optimize adjuvant treatment of coloncancer (CC). Standard adjuvant chemotherapy using 5-fluorouracil (FU) and folinic acid (FA) was compared with a combination including irinotecan (Folfiri). The aim of the present report was to analyze overall survival (OS) after long-term follow-up, to summarize final recurrence rates (...) in 17 (12.8%) patients treated with FUFA and in 50 (36.8%) patients treated with Folfiri. Recurrences occurred in 46 of 133 (34.6%) and in 47 of 136 (34.6%) patients who received FUFA and Folfiri, respectively. 5-year OS rates were 69.9% (95% confidence interval (CI): 61.2-77.1) for FUFA and 72.7% (95% CI: 63.9-79.8) for Folfiri. OS was associated with tumor grading (1 & 2 vs. 3), tumor sub-stage (II vs. IIIa vs. IIIb vs. IIIc), and tumor location (left vs. right colon).Folfiri cannot be generally
Mortality From Postscreening (Interval) ColorectalCancers Is Comparable to That From Cancer in Unscreened Patients-A Randomized Sigmoidoscopy Trial Endoscopic screening for colorectalcancer (CRC) is performed at longer time intervals than the fecal occult blood test or screenings for breast or prostate cancer. This causes concerns about interval cancers, which have been proposed to progress more rapidly. We compared outcomes of patients with interval CRCs after sigmoidoscopy screening vs (...) diagnosed with CRC 30 days or longer after screening (interval cancer group, n = 163) and individuals diagnosed with CRC in the nonscreened group (controls, n = 1740). All CRCs in the control group were identified when they developed symptoms (clinically detected CRCs). Analyses were stratified by cancer site. We used Cox regression to estimate hazard ratio (HRs), adjusted for age and sex.Over the follow-up period, 43 individuals in the interval cancer group died from CRC; among controls, 525 died from
Sequential Versus Combination Therapy of Metastatic ColorectalCancer Using Fluoropyrimidines, Irinotecan, and Bevacizumab: A Randomized, Controlled Study-XELAVIRI (AIO KRK0110) The XELAVIRI trial investigated the optimal treatment strategy for patients with untreated metastatic colorectalcancer. We tested the noninferiority of initial treatment with a fluoropyrimidine plus bevacizumab, followed by the addition of irinotecan at first progression (arm A) versus upfront use of fluoropyrimidine
Colon capsule endoscopy (CCE-2) for the detection of colorectal polyps and cancer in adults with signs or symptoms of colorectalcancer or at increased risk of colorectalcancer SHTG Advice Statement | 1 Advice Statement 014-18 November 2018 Advice Statement Colon capsule endoscopy (CCE-2) for the detection of colorectal polyps and cancer in adults with signs or symptoms of colorectalcancer or at increased risk of colorectalcancer Advice for NHSScotland Colon capsule endoscopy (CCE-2 (...) ) is not recommended for routine use in NHSScotland for the detection of colorectal polyps and cancer. The clinical effectiveness evidence is currently limited, no relevant published evidence on the cost effectiveness of the technology was identified, and its place in the patient care pathway has still to be established. CCE-2 may however be considered as an additional testing option in patients who are able to undergo the intensive bowel cleansing needed for CCE-2 and who have contraindications for optical
Making Patients Fit for Surgery: Introducing a Four Pillar Multimodal Prehabilitation Program in ColorectalCancer. Considering the relation between preoperative functional capacity and postoperative complications, enhancing patients' functional capacity before surgery with a prehabilitation program may facilitate faster recovery and improve quality of life. However, time before surgery is short, mandating a multimodal and high-intensity training approach. This study investigated feasibility (...) for colorectalcancer patients is feasible, safe, and effective. A randomized controlled trial (NTR5947) was initiated to determine whether prehabilitation may lower morbidity and mortality rates in colorectal surgery.
, Shibata M, Gonda K, et al. Serum levels of vascular endothelial growth factor are increased and correlate with malnutrition, immunosuppression involving MDSCs and systemic inflammation in patients with cancer of the digestive system. Oncol Lett 5 (2013): 1682-1686. Wei SC, Liang JT, Tsao PN, et al. Preoperative Serum Placenta Growth Factor Level Is a Prognostic Biomarker in ColorectalCancer. Dis Colon Rectum 9 (2009): 1630-1636. Werther K, Christensen IJ, Nielsen HJ. Determination of vascular (...) . Profiling of cytokines, chemokines and other soluble proteins as a potential biomarker in colorectalcancer and polyps. Cytokine 99 (2017): 35-42. Kemik O, Sumer A, Kemik AS, et al. The relationship among acute-phase response proteins, cytokines and hormones in cachectic patients with coloncancer. World J Surg Oncol 8 (2010): 85-91. Kemik O, Kemik AS, Begenik H, et al. The relationship among acute-phase responce proteins, cytokines, and hormones in various gastrointestinalcancer types patients
General medicine: Individuals with high-risk adenomas are at elevated risk for colorectalcancer Individuals with high-risk adenomas are at elevated risk for colorectalcancer | BMJ Evidence-Based Medicine Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers (...) of institutional accounts Username * Password * your user name or password? You are here Individuals with high-risk adenomas are at elevated risk for colorectalcancer Article Text Commentary General medicine Individuals with high-risk adenomas are at elevated risk for colorectalcancer Joseph C Anderson 1 , 2 Statistics from Altmetric.com Commentary on: Click B, Pinsky PF, Hickey T, et al . Association of colonoscopy adenoma findings with long-term colorectalcancer incidence. JAMA 2018;319:2021–2031. Context
with the Preferred Reporting Items for Systemic Review and Meta-Analyses statement. Search strategy Clinical trials were retrieved from eight databases including Wanfang date, CNKI, Pubmed, Cqvip, MEDLINE, Cochrane, CBM, and Springer LINK as well as from conference papers and theses. Terms retrieved in databases were as the following: postoperative coloncancer, rectal cancer, rectum cancer, colorectalcancer or largebowelcancer, and herb, herbal medicine, Zhong Yao, Zhong Cao Yao, Zhong Yi Yao, Chinese (...) decoction in the treatment of coloncancer operation and observe diarrhea after chemotherapy. Mod J Integr Tradit Chin West Med 2010;19:2131-2. Mao XL, Huang M. Clinical observation of adverse reaction of chemotherapy with Jianpi Yiqi alleviates post operation of colorectalcancer. J Shandong University of Traditional Chinese Med 2005:128-9. Qian Y, Huang X, Liu Q. Effect of Jianpi herbs on the recurrence and metastasis of postoperative colorectalCancer. China J Med 2009;16:80-1. Jadad AR, Moore RA
with papillary thyroid cancer that is the cribriform-morular variant, or hepatoblastoma Individuals with a diagnosis of CRC and>10 colorectal adenomas Individuals with a personal history of20 adenomas Individuals with multiple gastrointestinal hamartomatous polyps or serrated polyposis syndrome Individuals from a family with a known hereditary syndrome associated with CRC with or without a known mutation Individuals with a desmoid tumor, multifocal or bilateral CHRPE CHRPE, congenital hypertrophy of retinal (...) Screening for ColorectalCancer CLINICAL PRACTICE GUIDELINE Clinical Practice Guideline on Screening for ColorectalCancer in Individuals With a Family History of Nonhereditary ColorectalCancer or Adenoma: The Canadian Association of Gastroenterology Banff Consensus Desmond Leddin, 1,2, * David A. Lieberman, 3, * Frances Tse, 4 Alan N. Barkun, 5 Ahmed M. Abou-Setta, 6 John K. Marshall, 4 N. Jewel Samadder, 7 Harminder Singh, 6,8 Jennifer J. Telford, 9 Jill Tinmouth, 10 Anna N. Wilkinson, 11
Efficacy and Tolerability of First-Line Cetuximab Plus Leucovorin, Fluorouracil, and Oxaliplatin (FOLFOX-4) Versus FOLFOX-4 in Patients With RAS Wild-Type Metastatic ColorectalCancer: The Open-Label, Randomized, Phase III TAILOR Trial Cetuximab in combination with chemotherapy is a standard-of-care first-line treatment regimen for patients with RAS wild-type (wt) metastatic colorectalcancer (mCRC); however, the efficacy of cetuximab plus leucovorin, fluorouracil, and oxaliplatin (FOLFOX) has
. Perspective: These studies emphasize the extra-intestinal manifestations of colorectalcancer. The dental anomalies, commonly considered incidental findings, appear around 10 years before the clinical evidence of the intestinal polyps and the dental professional should be aware of these correlations. Since the gene mutation affects families, it is important to early detect, refer and map genetically these patients reducing the morbidity. The colorectalcancer is considered a public health issue, FAP (...) Dental radiograph as an opportunistic screening tool for a colorectalcancer syndrome (CAT#3342) UTCAT3342, Found CAT view, CRITICALLY APPRAISED TOPICs University: | | ORAL HEALTH EVIDENCE-BASED PRACTICE PROGRAM View the CAT / Title Dental radiograph as an opportunistic screening tool for a colorectalcancer syndrome Clinical Question Does dental radiograph serve as an opportunistic screening tool for early detection of extraintestinal manifestations of Familial Adenomatous Polyposis (FAP
Bevacizumab (Mvasi) - Metastatic ColorectalCancer (mCRC) or Locally Advanced, Metastatic or Recurrent Non-small Cell Lung Cancer (NSCLC) Search Page - Drug and Health Product Register Language selection Search and menus Search Search website Search Topics menu You are here: Summary Basis of Decision - - Health Canada Expand all Summary Basis of Decision (SBD) for Contact: Summary Basis of Decision (SBD) documents provide information related to the original authorization of a product
Minimally Invasive versus Abdominal Radical Hysterectomy for Cervical Cancer. There are limited data from retrospective studies regarding whether survival outcomes after laparoscopic or robot-assisted radical hysterectomy (minimally invasive surgery) are equivalent to those after open abdominal radical hysterectomy (open surgery) among women with early-stage cervical cancer.In this trial involving patients with stage IA1 (lymphovascular invasion), IA2, or IB1 cervical cancer and a histologic (...) , body-mass index, stage of disease, lymphovascular invasion, and lymph-node involvement; minimally invasive surgery was also associated with a lower rate of overall survival (3-year rate, 93.8% vs. 99.0%; hazard ratio for death from any cause, 6.00; 95% CI, 1.77 to 20.30).In this trial, minimally invasive radical hysterectomy was associated with lower rates of disease-free survival and overall survival than open abdominal radical hysterectomy among women with early-stage cervical cancer. (Funded
undergoing Surgery for GastrointestinalCancer A B S T R A C T Background: Identifying patient factors that impact the risks associated with and outcomes following resectional gastrointestinal (GI) cancer surgery is a potentially important strategy in achieving improved cancer survival. Methods: A search of Medline, BNI, Cochrane, Embase and CINAHL databases was performed, and English language publications of the period 1990–2016 reporting on the outcome of survival following gastrointestinalcancer (...) A Systematic Review of the Utility of Frailty and Sarcopenia Measures in Patients undergoing Surgery for GastrointestinalCancer A Systematic Review of the Utility of Frailty and Sarcopenia Measures in Patients undergoing Surgery for GastrointestinalCancer | Annals of Clinical Oncology | Science Repository | Open Access Menu / / / A Systematic Review of the Utility of Frailty and Sarcopenia Measures in Patients A Systematic Review of the Utility of Frailty and Sarcopenia Measures in Patients
Updated 5-year survival and exploratory T x N subset analyses of ACTS-CC trial: a randomised controlled trial of S-1 versus tegafur-uracil/leucovorin as adjuvant chemotherapy for stage III coloncancer Adjuvant Chemotherapy Trial of TS-1 for ColonCancer (ACTS-CC), a randomised phase III trial, demonstrated that adjuvant therapy with S-1 for stage III coloncancer was non-inferior in 3-year disease-free survival (DFS) to that of tegafur-uracil plus leucovorin (UFT/LV). We updated DFS (...) and overall survival (OS) and performed T x N subset analysis.A total of 1518 patients with curatively resected stage III coloncancer were randomly assigned to receive S-1 (80-120 mg/day on days 1-28 every 42 days, four courses) or UFT/LV (UFT: 300-600 mg/day and LV: 75 mg/day on days 1-28 every 35 days, five courses).The 5-year DFS rates of the S-1 and UFT/LV group were 70.2 % and 66.9 %, respectively (HR 0.88; 95% CI 0.74 to 1.06; p=0.177), and non-inferiority of DFS was reconfirmed with a median
Geographical Variations in the Clinical Management of ColorectalCancer in Australia: A Systematic Review Geographical Variations in the Clinical Management of ColorectalCancer in Australia: A Systematic Review | JCO Global Oncology Search in: Menu > > > > Article Tools Track 2 – Advances in Screening and Early Detection Article Tools OPTIONS & TOOLS COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/jgo.18.83400 Journal of Global Oncology - published online before print (...) September 28, 2018 Geographical Variations in the Clinical Management of ColorectalCancer in Australia: A Systematic Review 1 x F. Crawford-Williams , 1 x S. March , 1 x M. Ireland , 1 x A. Rowe , 1 x B. Goodwin , 2 x S. Chambers , 3 x J. Aitken , 1 x J. Dunn 1University of Southern Queensland, Springfield Central, Australia; 2Menzies Health Institute Queensland, Southport, Australia; 3Cancer Council Queensland, Brisbane, Australia Abstract Background: Colorectalcancer (CRC) presents considerable
Background: Population mail-out bowel screening programs are a convenient, cost-effective and sensitive method of detecting colorectalcancer (CRC). Despite increased survival rates associated with early detection of CRC, in many countries 50% or more of eligible individuals do not participate in such programs, resulting in a substantial amount of cancers progressing undetected and wasted public health resources. Aim: The current study aimed to systematically review all of the interventions that have (...) Strategies for Increasing Participation in Mail-out ColorectalCancer Screening Programs. A Systematic Review and Meta-Analysis Strategies for Increasing Participation in Mail-out ColorectalCancer Screening Programs. A Systematic Review and Meta-Analysis | JCO Global Oncology Search in: Menu > > > > Article Tools Track 1 – Motivating prevention and healthy behaviours Article Tools OPTIONS & TOOLS COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/jgo.18.74700 Journal